Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 06/07/20
AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis PatientsPRNewsWire • 06/06/20
Pharma Giant AbbVie Enters Ring With A Potential Coronavirus TreatmentInvestors Business Daily • 06/05/20
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19PRNewsWire • 06/05/20
5 High-Yield Blue-Chips I'm Buying For My Retirement Portfolio In This Overvalued MarketSeeking Alpha • 06/04/20
Increased Earnings Estimates Seen for AbbVie (ABBV): Can It Move Higher?Zacks Investment Research • 06/03/20
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus ImmunityZacks Investment Research • 06/01/20
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic ArthritisPRNewsWire • 06/01/20
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal WomenPRNewsWire • 05/29/20